Gilead Holding Up at $33 on Exhaustion of Negativity
Gilead (GILD) has finally caught some bids today up 0.5% on a volume of 23M (Ave. volume 12M) shares! Among the supporters of the stock are Leerink Swann who maintain their "Market Outperform" and price target of low 40's and JPMorgan who reiterate their "Overweight"and reduced target of $5...
Earnings Reports:Gilead (GILD) and Meridian (VIVO) Get Mixed Reviews
Gilead (GILD) Down on Missed Estimates-Is the Worst Finally Over for the Stock? Despite its stock being down over 30% from Q1 highs and earnings downgrades in April as a fallout from healthcare reform, the Company still disappoints Wall Street with Net Income of $712.1M or 79 cents a share up...
Funding of Technology Start-Ups and Campus Incubators
The story below published in the June 25 NYT merits further development. We are compiling data on other successful University start-ups and incubators such as the M.I.T deals in the article. The boom in campus incubators with a focus on commercializing inventions and nurturing start-up...
News Update: Hospital Costs Can Go Up as a Result of Bad Trades
The trading mentality and derivatives debacle that infected our financial system has impacted the financial health of hospitals. Who knew hospital management could do interest- rate swaps? They got crushed and now they are suing Wall Street firms. See WSJ story below. Hospitals Sue Wall Street...
Biomarker Diagnostics Drive Personalized Medicine #1 Update
But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and...